Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada.
A $100 million gift to UCSF's renowned Memory and Aging Center (MAC). It is the first gift to name a UCSF division, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback